{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:57:50Z","timestamp":1792688270177,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ccell.2021.11.012","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:29:13Z","timestamp":1640255353000},"page":"88-102.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"title":["Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance"],"prefix":"10.1016","volume":"40","author":[{"given":"Felicity","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-5452","authenticated-orcid":false,"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6750-5244","authenticated-orcid":false,"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-2065","authenticated-orcid":false,"given":"Venkateswar","family":"Addala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Nones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarem J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5025-8120","authenticated-orcid":false,"given":"Vanessa","family":"Lakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-1383","authenticated-orcid":false,"given":"Stephen H.","family":"Kazakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-0406","authenticated-orcid":false,"given":"Peter M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros T.","family":"Koufariotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-2496","authenticated-orcid":false,"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-434X","authenticated-orcid":false,"given":"Andrew J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-806X","authenticated-orcid":false,"given":"Robyn P.M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-3132","authenticated-orcid":false,"given":"Kerwin F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4598","authenticated-orcid":false,"given":"John V.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4760-1033","authenticated-orcid":false,"given":"Nicholas K.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-0013","authenticated-orcid":false,"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2021.11.012_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2217\/imt-2015-0002","article-title":"The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis","volume":"8","author":"Aguiar","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ccell.2021.11.012_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib5","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.xcrm.2020.100139","article-title":"Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib7","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2021.11.012_bib8","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2021.11.012_bib103","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Methodol"},{"key":"10.1016\/j.ccell.2021.11.012_bib9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/bloodadvances.2016000786","article-title":"Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets","volume":"1","author":"Bolen","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2021.11.012_bib10","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1038\/s41467-018-05570-1","article-title":"Pan-cancer deconvolution of tumour composition using DNA methylation","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"10.1016\/j.ccell.2021.11.012_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","author":"Coppola","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ccell.2021.11.012_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2021.11.012_bib14","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","article-title":"RNA-SeQC: RNA-seq metrics for quality control and process optimization","volume":"28","author":"DeLuca","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2021.11.012_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/pcmr.12153","article-title":"Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma","volume":"26","author":"Dutton-Regester","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib19","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2021.11.012_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib22","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2021.11.012_bib23","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.3107","article-title":"Scaling regression inputs by dividing by two standard deviations","volume":"27","author":"Gelman","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib25","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2021.11.012_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2021.11.012_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib28","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/cancers13133186","article-title":"Clinical and molecular heterogeneity in patients with innate resistance to anti-pd-1\u00a0+\/\u2212 anti-ctla-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets","volume":"13","author":"Gide","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ccell.2021.11.012_bib29","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2021.11.012_bib30","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2021.11.012_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib34","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","article-title":"Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non\u2013small cell lung carcinoma or urothelial cancer treated with durvalumab","volume":"24","author":"Higgs","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class i binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"key":"10.1016\/j.ccell.2021.11.012_bib36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bioinformatics\/btx604","article-title":"Detecting presence of mutational signatures in cancer with confidence","volume":"34","author":"Huang","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","article-title":"pVAC-Seq: a genome-guided in\u00a0silico approach to identifying tumor neoantigens","volume":"8","author":"Hundal","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib40","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T\u00a0cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib41","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1073\/pnas.0538056100","article-title":"Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T\u00a0cells in influenza virus-infected mice","volume":"100","author":"Johnson","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2021.11.012_bib42","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing Identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib43","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"J\u00f6nsson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib44","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients","volume":"21","author":"Kakavand","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib45","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib46","doi-asserted-by":"crossref","first-page":"e74380","DOI":"10.1371\/journal.pone.0074380","article-title":"Somatic point mutation calling in low cellularity tumors","volume":"8","author":"Kassahn","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2021.11.012_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","article-title":"Efficacy of PD-1\u2013based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma","volume":"116","author":"Kreft","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2021.11.012_bib48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib49","doi-asserted-by":"crossref","first-page":"e1000217","DOI":"10.1371\/journal.pcbi.1000217","article-title":"Inferring pathway activity toward Precise disease classification","volume":"4","author":"Lee","year":"2008","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ccell.2021.11.012_bib50","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib51","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"2013","journal-title":"ArXiv"},{"key":"10.1016\/j.ccell.2021.11.012_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib53","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database Hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2021.11.012_bib55","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ccell.2021.11.012_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.ccell.2021.11.012_bib58","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/pcmr.12831","article-title":"Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma","volume":"33","author":"Mason","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib59","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T\u00a0cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib60","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2021.11.012_bib62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/pcmr.12745","article-title":"PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival","volume":"32","author":"Micevic","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/bioinformatics\/btt684","article-title":"ChAMP: 450k chip analysis methylation pipeline","volume":"30","author":"Morris","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib65","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1002\/cncr.27693","article-title":"Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma","volume":"118","author":"Murali","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2021.11.012_bib66","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2021.11.012_bib68","doi-asserted-by":"crossref","first-page":"r105","DOI":"10.1186\/gb-2013-14-9-r105","article-title":"Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia","volume":"14","author":"Nordlund","year":"2013","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2021.11.012_bib69","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41467-017-01018-0","article-title":"Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers","volume":"8","author":"Ock","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib70","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T\u00a0cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2021.11.012_bib72","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2021.11.012_bib73","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41591-020-0818-3","article-title":"Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy","volume":"26","author":"P\u00e9rez-Guijarro","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib74","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2021.11.012_bib75","first-page":"544","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T\u00a0cells","volume":"387","author":"Powles","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib76","doi-asserted-by":"crossref","first-page":"15.9.1","DOI":"10.1002\/cpbi.17","article-title":"ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data","volume":"56","author":"Raine","year":"2016","journal-title":"Curr. Protoc. Bioinforma."},{"key":"10.1016\/j.ccell.2021.11.012_bib77","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2021.11.012_bib78","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib79","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2021.11.012_bib80","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib81","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib83","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib84","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2021.11.012_bib85","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib86","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2021.11.012_bib87","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib88","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2021.11.012_bib89","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib91","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2021.11.012_bib92","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib93","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib94","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/bioinformatics\/bts680","article-title":"A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450\u00a0k DNA methylation data","volume":"29","author":"Teschendorff","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2021.11.012_bib95","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2021.11.012_bib96","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2021.11.012_bib97","series-title":"Bioinformatics","first-page":"2699","article-title":"BAM-matcher: a tool for rapid NGS sample matching","author":"Wang","year":"2016"},{"key":"10.1016\/j.ccell.2021.11.012_bib98","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2021.11.012_bib100","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib101","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2021.11.012_bib102","first-page":"e22","article-title":"Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes","volume":"45","author":"Zhou","year":"2017","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1016\/j.ccell.2025.01.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000}}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610821006127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610821006127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:06:44Z","timestamp":1761523604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610821006127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1535610821006127"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2021.11.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741367912.793593775","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2021.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}